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ABSTRACT
Aims The study aims to determine the direct costs and
comparative cost-effectiveness of latest-generation dual-
source computed tomography (DSCT) and invasive
coronary angiography for diagnosing coronary artery
disease (CAD) in patients suspected of having this
disease.
Methods The study was based on a previously
elaborated cohort with an intermediate pretest likelihood
for CAD and on complementary clinical data. Cost
calculations were based on a detailed analysis of direct
costs, and generally accepted accounting principles were
applied. Based on Bayes’ theorem, a mathematical
model was used to compare the cost-effectiveness of
both diagnostic approaches. Total costs included direct
costs, induced costs and costs of complications.
Effectiveness was defined as the ability of a diagnostic
test to accurately identify a patient with CAD.
Results Direct costs amounted to V98.60 for DSCT and
to V317.75 for invasive coronary angiography. Analysis
of model calculations indicated that cost-effectiveness
grew hyperbolically with increasing prevalence of CAD.
Given the prevalence of CAD in the study cohort (24%),
DSCT was found to be more cost-effective than invasive
coronary angiography (V970 vs V1354 for one patient
correctly diagnosed as having CAD). At a disease
prevalence of 49%, DSCT and invasive angiography were
equally effective with costs of V633. Above a threshold
value of disease prevalence of 55%, proceeding directly
to invasive coronary angiography was more cost-
effective than DSCT.
Conclusions With proper patient selection and
consideration of disease prevalence, DSCT coronary
angiography is cost-effective for diagnosing CAD in
patients with an intermediate pretest likelihood for it.
However, the range of eligible patients may be smaller
than previously reported.
INTRODUCTION
Coronary artery disease (CAD) is the leading cause
of death in the USA and Europe and can be
considered as a major public health problem
worldwide.1e3 The estimated total cost of CAD in
Europe for 2008 is V49 billion.4 The significant
social and economic impact of CAD makes its
timely and efficient diagnosis a matter of the
utmost importance.5
Various imaging modalities have recently
contributed to the improvement in detection of
patients with suspected CAD.6 In particular,
contrast-enhanced multi-detector computed
tomography (MDCT) has emerged as a valuable
non-invasive tool to evaluate coronary arteries.
Cardiac MDCT has rapidly evolved from 4-row
detector systems to latest-generation scanners
including 320-row detector row systems and dual-
source computed tomography (DSCT) systems.7e12
Due to technological advancements, the diagnostic
quality of MDCT coronary angiography has
improved substantially. Several studies have shown
an excellent correlation with invasive coronary
angiography for the diagnosis of significant
CAD.13e15 Recent studies suggested the superior
cost-effectiveness of MDCTcoronary angiography in
diagnosing CAD. However, those studies were
mainly computer simulations of idealised model
situations. Importantly, only basic 64-row MDCT
systems were studied and some results were
constrained by methodological inaccuracies, such as
applying inconsistent cost-accounting practices.16e19
Thus, the true cost position of latest-generation
MDCT scanners in evaluating patients with
suspected CAD remains somewhat unclear.
The current study therefore aimed to determine
the direct costs and cost-effectiveness of DSCT
coronary angiography as an alternative to invasive
coronary angiography in a patient cohort with an
intermediate likelihood of CAD.
MATERIALS AND METHODS
Patients
We analysed the direct costs for diagnostic coronary
imaging at a single centre. The study included
a total of 90 consecutive patients without a history
of CAD who were referred for invasive coronary
angiography. Inclusion criteria and clinical details of
the patients have been described in a previous
article.20 Briefly, the patients (mean age 5868 years,
63% male) had uninterpretable or equivocal non-
invasive stress tests and an intermediate pretest
likelihood for significant CAD according to the
score of Morise et al (9e15 points).21 Presenting
symptoms included typical angina (n¼20), atypical
angina (n¼53) and dyspnoea (n¼17). Patients with
a positive stress test and/or a high (>15 points) or
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from the study. All patients underwent DSCT the day before
they underwent invasive coronary angiography. The study
protocol was approved by the institutional review board, and
written informed consent was obtained from all patients.
DSCT coronary angiography
Full details of the scanning protocol have been published previ-
ously, and only a brief summary is described here.20 22 CT
coronary angiography was performed using a DSCT scanner
(Somatom Definition, Siemens Healthcare, Forchheim,
Germany), which uses two x-ray sources and two detectors
simultaneously. The parameters for the acquisition were
a gantry rotation time of 0.33 s, a tube voltage of 120 kV for
both tubes, a tube current of 560 mAs (using modulation), a slice
collimation of 6430.6 mm and a pitch of 0.2e0.44 adapted to
heart rate. Prior to the scan, no negative chronotropic premed-
ication was given. A body-weight-adapted (1.25 cm3/kg body
weight) volume of the contrast agent iopromide (Ultravist 370,
Schering, Berlin, Germany) was injected continuously during
a period of 20 s followed by a saline flush (100 cm3 at 5 cm3/s).
Axial images were reconstructed at a slice thickness of 0.75 mm
and an increment of 0.5 mm using a B26 kernel and retrospective
ECG gating. The DSCT data sets were read by an experienced
physician immediately after the exam using a dedicated cardiac
workstation (Leonardo, Siemens Healthcare). Each coronary
segment was judged as non-stenosed (no stenosis, <50%),
intermediately diseased (>50% to <75% diameter stenosis) or
significantly diseased (>75% diameter stenosis) using a modified
American Heart Association segment model.23
Invasive coronary angiography
An independent external cardiologist determined the indication
for invasive coronary angiography. In all patients, conventional
coronary angiography was performed using standard techniques
1 day after DSCT coronary angiography. Vascular access was
obtained through a femoral approach using the Seldinger tech-
nique with 6F or 7F catheters. At least three standard projections
including a 458 left anterior oblique, a 308 right anterior oblique
and a 458 left anterior and 308 cranial projection were acquired
for both coronary arteries with a single-plane, floor-mounted
angiography system (Coroskop HIP, Siemens Healthcare). For
coronary angiography, iomeprol (Imeron 350, Bracco Altana,
Konstanz, Germany) was administered. Invasive coronary
angiography served as the reference standard for the determi-
nation of CAD. Thus, all coronary angiograms were evaluated
by quantitative coronary angiography (QuantCor, Siemens
Healthcare). For coronary artery lesions, the mean diameter
reduction was determined in two projections. The DSCT diag-
nostic criteria for intermediate and significant CAD also applied
to invasive coronary angiography.
Cost analysis
In the economical evaluation, the costs (in euros) of both diag-
nostic approaches were identified through a detailed analysis of
all involved procedures. Direct costs were composed of three
categories: diagnostic-specific equipment costs, materials and
supplies costs and personnel costs. Equipment costs included
purchasing, maintenance and repair (excluding major improve-
ments and system upgrades) as well as financing costs (average
annual interest payments). Installation contracts provided for
a defects liability period. On-site clinical training was also
included as part of the contract. Cost of materials and supplies
reflected market prices paid to manufacturers and vendors.
Occupancy costs included heating, air-conditioning, light,
cleaning, insurance, security and others. Personnel costs were
salaries and wages including social security, pension and other
related contributions. Other analyses (eg, ECG, blood tests and
physical examination) carried out before the actual procedures
were not taken into account and were considered identical for
both diagnostic strategies. Hospitalisation costs before and after
the procedure, except for the 6-h observation period following
diagnostic catheterisation, were also not taken into account
because they were dependent on comorbidities and other
patient-independent factors.24 Contributions to overhead were
not included.
In the cost analysis, the following general assumptions were
taken into account: equipment lifetime for all systems was set at
8 years. Operational hours for both the DSCT scanner and the
cardiac catheterisation laboratory were 8 h/day, 254 days/year.
All involved physicians, nurses and technicians were salaried
hospital employees. Thus, personnel costs were calculated
according to collective agreements for German public service
employees including additional provisions for vacation, sick
leave and continuing education (25% on average). Where appli-
cable, costs included value-added tax at 19%.
Cost-effectiveness analysis
A cost-effectiveness analysis was conducted from the provider
perspective. The key effectiveness criterion was the ability of
a diagnostic test to identify accurately a patient who has CAD
based on morphological criteria describing coronary artery
luminal integrity.25e27 This straightforward approach assumes
that the goal of a test is to make a diagnosis.27 Cost-effectiveness
was defined as cost per effect.26 27
Direct Costs þ Induced Costs
Effectiveness
Total costs were calculated as direct costs (as established by
the cost analysis) times the number of patients tested plus the
induced costs (the number of patients tested multiplied by the
costs of complications produced by test procedures or of CAD
missed by false-negative test results).25e27 By definition, invasive
coronary angiography was the gold-standard test in the cost-
effectiveness analysis with a 100% diagnostic accuracy (sensitivity
(SnA) and specificity (SpA) of invasive coronary
angiography¼100%) and no non-diagnostic results. The mathe-
matical model to compare cost-effectiveness of DSCT coronary
angiography and invasive angiography is a modification of the
equations of Bayes’ theorem and has been previously described.26 27
Specifically, the model involves the equations below (box 1
shows parameters used in equations). In the first algorithm,
DSCT coronary angiography would be performed first followed
by invasive angiography but only if DSCTcoronary angiography
is positive or non-diagnostic (figure 1A).








In the alternative diagnostic algorithm, invasive coronary
angiography would be the first and only test to diagnose CAD
(figure 1B).
2. Invasive coronary angiography
c. Costs¼NA3(DA+RA3C) whereas NA¼1.0
d. Effectiveness¼NA3P
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Costs of complications (C) are difficult to estimate.16 26 27 For
this purpose, previously published data were combined. It was
assumed that the typical complication of both diagnostic tests
or of untreated CAD would be non-fatal myocardial infarction
(or cerebrovascular, for invasive angiography), requiring hospi-
talisation, rehabilitation, chronic medication and repeated
follow-up examinations. On average, conservative cost estimates
for a serious complication amounted to V14 478.16 17 28e30
Complication rates for MDCT (RCT¼0.004%) and elective
invasive coronary angiography (RA¼0.05%) were derived from
the literature.16 24 31 The potential risk of radiation-induced
malignancies from a single DSCT or angiography exposure is
difficult to assess and was therefore not incorporated in the
model assumptions. For the same reason, the costs of follow-up
of incidental non-cardiac findings on DSCTwere not included.32
In the subgroup of patients with false-negative DSCT coronary
angiography, a 15% rate (RF) of non-fatal myocardial infarction
over 10 years was assumed.27 Costs associated with a false-
negative test did not include costs for malpractice settlement or
costs of a trial. Future complication-related costs were
discounted annually at a rate of 3%. Cost-effectiveness calcula-
tions were carried out over the full range of CAD prevalence (P)
(P¼10e100%) under special consideration of our intermediate
risk cohort.
Sensitivity analysis
A sensitivity analysis was performed to evaluate whether some
key parameters used in the mathematical model are robust
within a certain range of uncertainty. Thus, cost-effectiveness
calculations were repeated after (1) increasing and decreasing the
rates of complications associated with invasive coronary angi-
ography (RA¼0.1% and 0.01%), (2) taking into account higher
and lower costs of complications (C¼V25 000 and V10 000), (3)
increasing and decreasing DSCT coronary angiography sensi-
tivity (SnCT¼98% and 92%) and specificity (SpCT¼93% and
87%), (4) assuming higher and lower rates of complications
resulting from false-negative DSCT coronary angiography
(RF¼30% and 10%) and (5) increasing and decreasing the
discount rate (5% and 0%).
Statistical analysis
Confidence intervals were determined for sensitivity, for
specificity and for negative and positive predictive values on
a per-patient basis. The statistical analysis was made using the
MedCalc program (MedCalc, Mariakerke, Belgium).
RESULTS
Diagnostic accuracy to detect CAD
Dual-source CT image quality was graded sufficient for analysis
in 88 of 90 (98%) patients. Two patients with insufficient image
quality because of motion artefacts were excluded from the
accuracy analysis (rate of non-diagnostic DSCT coronary
angiography (NDxCT)¼2%). On a per-patient basis and as
diagnosed as having invasive coronary angiography, 9 patients
had at least one coronary artery stenosis >75% and 12 patients
had at least one stenosis that was 50% to 75% of luminal
diameter. Hence, the prevalence of CAD (P) was 24%. All
patients with a stenosis >75% and 11 of 12 patients with
a stenosis ranging from 50% to 75% were correctly identified by
DSCT. In seven patients without significant CAD (stenosis
>50%), three patients were incorrectly diagnosed by DSCT to
have at least one stenosis >75% and four patients were incor-
rectly diagnosed to have at least one stenosis of between 50%
and 75%. The data expressing patient-based diagnostic accuracy
are given in table 1. Importantly, overall sensitivity (SnCT) and
specificity (SpCT) of DSCTcoronary angiography were 95% and
90%, respectively. Results of DSCT coronary angiography were
false-negative in one patient (NF¼1%). Further details of this
Box 1 Parameters used in calculations
< DCT, direct costs for DSCT coronary angiography
< DA, direct costs for invasive coronary angiography
< C, average costs of a complication (assumed to be non-fatal
myocardial infarction or stroke)
< RCT, rate of complications with DSCT coronary angiography
< RA, rate of complications with invasive coronary angiography
< RF, rate of complications per 10-year follow-up period for
patients with CAD and false-negative tests
< SnCT, sensitivity of DSCT coronary angiography
< SpCT, specificity of DSCT coronary angiography
< SnA, sensitivity of invasive coronary angiography
< SpA, specificity of invasive coronary angiography
< NDxCT, rate of non-diagnostic DSCT coronary angiography
< NCT, number of patients having DSCT coronary angiography
< NA, number of patients having invasive coronary angiography
< NF, number of patients with false-negative DSCT coronary
angiography who do not have invasive coronary angiography
< P, prevalence of CAD in patient cohort
CAD, coronary artery disease; DSCT, dual-source computed
tomography.
Figure 1 Decision tree model for patients (Pt) presenting with
suspected coronary artery disease (CAD). Strategy A involved dual-
source computed tomography (DSCT) coronary angiography. Patients
with positive or non-diagnostic (NDx) DSCT underwent invasive coronary
angiography (Angio), which either confirmed or refuted the DSCT
diagnosis. Patients with false-negative DSCT findings were at risk for
myocardial infarction (MI) from undetected CAD. In strategy B, invasive
coronary angiography was the first and only test to diagnose CAD.
Table 1 Patient-based diagnostic accuracy of DSCT to detect coronary
artery stenoses
Degree of
stenoses Sensitivity Specificity PPV NPV
50e75% 11/12 (92%) 63/67 (94%) 11/15 (73%) 59/60 (99%)
95% CI 62% to 99% 85% to 98% 44% to 92% 91% to 100%
>75% 9/9 (100%) 76/79 (96%) 9/12 (75%) 76/76 (99%)
95% CI 66% to 99% 89% to 99% 42% to 94% 95% to 100%
All >50% 20/21 (95%) 60/67 (90%) 20/27 (74%) 60/61 (99%)
95% CI 76% to 99% 80% to 95% 58% to 89% 91% to 99%
DSCT, dual-source computed tomography; NPV, negative predictive value; PPV, positive
predictive value.
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cohort have been reported previously.20 No actual complications
related to DSCT or invasive coronary angiography were
observed. However, for calculation purposes, the above-described
rates of complications were used.
Cost analysis
DSCT coronary angiography
Findings on direct costs for DSCT coronary angiography are
presented in table 2. Unit costs represent either purchasing costs,
annual average costs or costs for a given quantity of material
(quantities in brackets). The calculated costs per examination
are shown in the right column. The calculations were based on
the above-mentioned general assumptions for cost analysis and,
in addition, on specific time requirements for DSCT coronary
angiography. These included 15 min of total DSCTscanner room
time and 30 min for postprocessing, reporting and archiving on
a separate workstation. Cardiologists and radiographers were
allotted 20 and 25 min per examination, respectively. Purchasing
costs involved installation costs as well as all associated building
renovations necessary to accommodate the DSCT scanner. The
manufacturer ’s full service contract included x-ray tubes and
preventive maintenance. Surface area for installation was 40 m2,
providing sufficient floor space for the DSCT scanner room as
well as for the control room. On average, 107 cm3 of contrast
agent and 100 cm3 of saline were used per patient. The total
direct cost of a DSCT coronary angiography (DCT) study
amounted to V98.60.
Invasive coronary angiography
Table 3 lists the costs associated with invasive coronary angi-
ography. Calculated effective costs per examination are depicted
in the right column. Overall cardiac catheterisation laboratory
utilisation time for a diagnostic coronary angiography was
30 min. A cardiologist was present for 30 min, a radiographer
was present for 35 min and a nurse was present for 50 min (the
latter time included an average of 15 min for patient care during
the 6-h postcatheterisation observation period). In general,
preparation and documentation of a case were included in the
times allotted. The main components of the cardiac catheter-
isation laboratory infrastructure were the single-plane angiog-
raphy system and the haemodynamic recording system.
Equipment costs included all costs of installation and imple-
mentation. The full service contract covered all travel and
personnel costs for unscheduled breakdown visits as well as
major replacement items such as image intensifiers and x-ray
tubes. The size of the cardiac catheterisation laboratory was
85 m2, allowing for adequate space for procedure, control,
technical and storage rooms. Adjacent to the catheterisation
laboratory, there was an eight-bed holding area (approximately
9 m2 floor space per bed) with telemetry monitoring. As far as
materials and supplies are concerned, a multiplication factor of
two had to be applied for compact disks and a factor of four for
10-cm3 syringes, sterile compresses (10 packs) and disposable
ECG electrodes. A mean of 80 ml of contrast agent was used per
patient. Direct invasive coronary angiography costs (DA)
totalled V317.75.
Cost comparisondDSCT versus invasive coronary angiography
Summarised cost categories are displayed in table 4. Equipment
costs were nearly the same for both diagnostic approaches.
However, materials and supplies costs of invasive coronary








Siemens Somatom Definition 1 612 000.00 24.79
Separate CT workstation 68 310.00 2.10
DSCT full service contract (per year) 114 850.00 14.13
Dual-head injector 42 513.00 0.65
Injector service contract (per year) 2200.00 0.27
Electricity, water and IT connectivity (per year) 10 575.50 1.73
Occupancy costs (40 m2) (per year) 7508.40 1.23
Financing costs (interest rate 5.0%) (per year) 44 627.00 5.49
Materials and supplies costs
Contrast agent (Ultravist 370) (100 cm3) 6.50 6.95
Saline (500 cm3) 0.73 0.15
Intravenous cannula (18G) (including
disinfectant and dressing)
0.62 0.62
Dual syringe kit with tubing and connector 9.09 9.09
Disposable ECG electrode 0.23 0.90
Archiving (PACS) 1.35 1.35
Personnel costs
Physician (per year) 107 359.20 18.64
Radiographer (per year) 49 920.00 10.50
Total 98.60
DSCT, dual-source computed tomography; IT, information technology; PACS, picture
archiving and communication system.












Full service contract (per year) 41 445.00 10.20
Electricity, water and IT connectivity
(per year)
8433.00 2.08
Occupancy costs (85 m2) (per year) 22 525.20 3.93
Holding area (9 m2/bed) (per year) 1689.39 4.99
Financing costs (interest rate 5.0%)
(per year)
25 075.00 6.17
Materials and supplies costs
Set of sterile gloves, gowns and drapes 53.31 53.31
Arterial puncture needle (18G) 2.11 2.11
Syringe 10 cm3 0.12 0.48
Standard catheter set (including JL, JR,
sheaths, guidewires and pigtail catheter)
50.39 50.39
Contrast agent (Imeron 350) (100 cm3) 7.22 5.78
Arterial blood sampling syringe 0.77 0.77
Local anaesthetics (Xylonest 2%) (20 cm3) 2.17 2.17
Heparin (5000 IU) 0.12 0.12
Glyceryl trinitrate (1 cm3) 0.07 0.07
Disposable infusion system 0.29 0.29
Disposable ECG electrode 0.23 0.90
Sterile compresses (10 packs) 0.05 0.20
Saline (500 cm3) 0.73 0.73
Sterile drapes for angiography system 2.30 2.30
Intravenous cannula (18G) (including
disinfectant and dressing)
0.62 0.62
Vascular closure device (Angioseal) 77.35 77.35
Archiving (CD) 0.39 0.78
Personnel costs
Cardiologist (per year) 107 359.20 27.96
Cardiac cath lab radiographer (per year) 49 920.00 14.58
Cardiac cath lab nurse (per year) 49 920.00 20.83
Total 317.75
CD, compact disk; IT, information technology; IU, international unit; JL, Judkins left
coronary diagnostic catheter; JR, Judkins right coronary diagnostic catheter.
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angiography were approximately 10-fold, and personnel
costs were nearly double when compared to DSCT coronary
angiography.
Cost per patient tested and cost-effectiveness
Figure 2 shows the cost per patient tested in relation to different
prevalences of CAD. These results indicate that the direct costs
only represented one component of total costs incurred by
a diagnostic test. The cost for DSCT coronary angiography
increased as a linear function of CAD prevalence. In contrast, the
cost for invasive coronary angiography did not increase signifi-
cantly. Figure 3 plots cost per effect (cost per patient with CAD
diagnosed accurately) versus increasing prevalences of CAD. As
cost per effect is the inverse of cost-effectiveness, the hyperbolic
decrease in cost per effect indicates increased cost-effectiveness.
Despite the increase in total cost with increasing prevalence of
CAD, cost-effectiveness improved with higher CAD prevalence
for both diagnostic tests. In comparison, DSCT coronary angi-
ography was more cost-effective up to a CAD prevalence of 48%.
Given the 24% CAD prevalence of the investigated patient
cohort, cost for one patient correctly diagnosed as having CAD
was V970 with DSCT and V1354 with invasive angiography
(figure 3). At a CAD prevalence of 49%, DSCT and invasive
angiography were equally effective with costs of V633. With
higher disease prevalences, invasive coronary angiography
became more cost-effective.
Sensitivity analysis
In order to evaluate the robustness of the mathematical model
and to address uncertainty, we systematically changed the
numerical values of some key parameters in the equations.
Increasing (0.1%) or decreasing (0.01%) the rates of complica-
tions associated with invasive coronary angiography changed
the cost-effectiveness threshold of DSCT significantly (52% and
47% CAD prevalence, respectively). With higher (V25 000) and
lower (V10 000) costs of complications, DSCT remained cost-
effective up to a CAD prevalence of 42% and 52%, respectively.
The most substantial changes occurred at maximally decreased
and increased diagnostic accuracies. However, DSCT coronary
angiography remained more cost-effective than invasive angi-
ography up to a disease prevalence of 41% and 55%, respectively.
After elevating (30%) and lowering (10%) the risk of non-fatal
myocardial infarction because of false-negative test results,
DSCT coronary angiography remained comparably more cost-
effective up to a CAD prevalence of 40% and 53%, respectively.
Using discount rates for future complication-related costs of 0%
and 5% (base case 3%), we found that DSCT was still cost-
effective up to a CAD prevalence of 46% and 51%, respectively.
Thus, sensitivity analysis revealed cost-effectiveness of well-
performed DSCT coronary angiography in diagnosing CAD up
to an average disease prevalence of 40%. When disease preva-




To the best of our knowledge, this is the first study to evaluate
the cost-effectiveness of a latest-generation DSCT scanner in
diagnosing CAD in a well-defined cohort of patients with an
intermediate pretest disease likelihood. For the first time,
generally accepted business accounting principles were applied
and the cost calculations were based on a detailed analysis
of direct costs. Compared to the gold standard of invasive
coronary angiography, DSCT coronary angiography was found
to be cost-effective up to an average disease prevalence of 40%.
Above a threshold value of disease prevalence of 55%,
proceeding directly to invasive coronary angiography was more
cost-effective than DSCT.
Assessment of cost-effectiveness
In the past years, there has been an increasing awareness of the
need to consider cost in medical decision-making.33 Cost-effec-
tiveness analysis can help medical decision-makers to target
scarce healthcare resources more efficiently and can guide
utilisation of latest-generation and often high-cost diagnostic
imaging modalities.34 35








Materials and supplies 19.06 198.37
Personnel 29.14 63.37
Total 98.60 317.75
DSCT, dual-source computed tomography.
Figure 2 The graph shows the cost per patient (Pt) tested on the
vertical axis for dual-source computed tomography (DSCT) and invasive
coronary angiography (Angio). Prevalence of coronary artery disease
(CAD) increases along the horizontal axis. Cost increases with CAD
prevalence for DSCT coronary angiography but not significantly for
invasive coronary angiography. DSCT showed lower cost than invasive
angiography with CAD prevalence <54% but higher costs with CAD
prevalence $54%.
Figure 3 The graph shows cost per effect (cost per patient with
coronary artery disease (CAD) diagnosed (Dx) correctly) on the vertical
axis. As the prevalence of CAD increases along the horizontal axis, the
cost per effect (or cost-effectiveness1) decreases. At low CAD
prevalence, cost per effect is lower for dual-source computed
tomography (DSCT) than for invasive coronary angiography (Angio).
Invasive angiography shows lower cost per effect than DSCT with CAD
prevalence >49%. The CAD prevalence of the investigated patient cohort
was 24% (also shown in the graph).
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A major challenge in cost-effectiveness analysis is the identi-
fication of all relevant costs. Importantly, costs should be defined
in an unambiguous way and should not be confused with
charges or reimbursement fees.33 Direct costs reflect the value of
resources that are actually paid for.33 36 The overall direct costs
of invasive coronary angiography were found to be about three
times the cost of DSCT coronary angiography, mainly due to
higher materials and supplies costs and personnel costs. This
ratio is markedly lower than those reported in previous studies,
which have found that the cost of invasive coronary angiog-
raphy exceeds that of 64-row MDCT coronary angiography up
to a factor of nine.16 17 19 However, the latter studies have, at
least partly, applied inconsistent cost-accounting practices, and
thus, the results might not be directly comparable. In particular,
reimbursement fees were misleadingly mixed with or were taken
as a surrogate for direct costs, resulting in disproportionately
high costs of invasive coronary angiography. Although the price
of a DSCTscanner significantly exceeds that of a 64-row MDCT
scanner, the comparably low cost ratio between DSCT and
invasive coronary angiography found in our data cannot be
attributed to higher DSCT purchasing costs. In fact, total direct
costs of DSCT were even lower than those of 64-row MDCT,
mainly due to a relative reduction in personnel costs.17 This cost
reduction may be, at least partly, achieved by DSCT features
such as imaging without b blockers, which minimises prescan
preparation, in-room time and the postscan observation period.
However, the main factor that contributes to the low cost ratio
between DSCT and invasive coronary angiography is the rela-
tively low direct costs of invasive coronary angiography,
reflecting an increasingly professional cardiac catheterisation
laboratory management and various cost containment strate-
gies.37 As this study assumes a healthcare provider ’s perspective
and not a societal one, indirect costs such as lost productivity
due to missed work were excluded.33 It was not our goal to
assess the impact of diagnostic tests of CAD on the welfare of
society.26 This more complex task would have required a coste
benefit analysis.33 38 Rather, the objective of the study is to
compare the costs of two diagnostic approaches to achieve the
same effect, that is, diagnosing CAD.
The diagnostic accuracy of DSCT to detect coronary artery
stenoses (table 1) was similar to that reported in other DSCT
studies.39 40 In patient populations comparable to those of our
current study, the clinical usefulness of 64-row MDCTcoronary
angiography has recently been corroborated.41 42 Compared to
single-source 64-row MDCT, DSCT coronary angiography
shows better image quality and provides comparable or slightly
improved diagnostic accuracy.43 44 It has been shown that the
pretest likelihood of CADmay impact the diagnostic accuracy of
MDCT coronary angiography.45 Thus, pooled diagnostic accu-
racies, stemming mainly from cohorts with high pretest likeli-
hoods (>80%), cannot be extrapolated to cohorts with low
(<20%) or intermediate (20e80%) pretest likelihoods.16 17 45
According to recent recommendations, MDCT coronary angi-
ography should only be carried out on selected patients, princi-
pally those who have an intermediate pretest likelihood of CAD
or who have uninterpretable or equivocal stress tests.46 MDCT
is of limited clinical value in patients with a high pretest like-
lihood of CAD because the majority of patients with symptoms
are likely to proceed straight to invasive coronary angiography
and particularly because angiography and percutaneous coro-
nary interventions are often done on the same occasion.45e47 In
patients with a low pretest likelihood of CAD, stress testing is
recommended because of low cost, safety and absence of
ionising radiation.46 47
Although the cost per patient tested increased linearly along
with an increase in disease prevalence (figure 2), cost-effective-
ness (cost per effect) analysis showed a hyperbolic decrease in
costs (figure 3). This observation is due to the fact that the
employed mathematical model defines a patient correctly diag-
nosed as having CAD as the effect in the cost-effectiveness
analysis and that this effect becomes more frequent with an
increase in disease prevalence.16 26 27 Specifically, the effect was
based on morphological criteria of coronary artery luminal
anatomy and integrity.48 Physiological testing, including
assessment of the functional significance of a coronary artery
stenosis or examining myocardial viability, was not addressed by
our study. Although both anatomical and physiological tests are
important in the management of patients suspected of having
CAD, they provide fundamentally different information and
their results might therefore not be directly comparable.16 At
low CAD prevalences, DSCT coronary angiography was more
cost-effective than invasive angiography (figure 3). It is perfectly
reasonable that negative DSCTresults will reduce the number of
invasive coronary angiographies at low disease prevalences
(<40%) because nearly all DSCT tests will be correct to rule out
CAD (high negative predictive value of DSCT coronary angiog-
raphy at lower prevalences of CAD) (table 1).45 47 48 In contrast,
at higher disease prevalences, DSCT starts to miss patients who
actually have CAD and the costs of complications resulting from
false-negative DSCT examinations decrease cost-effectiveness.
Above a threshold value of >55% disease prevalence, performing
invasive coronary angiography as the first and only test was
more cost-effective. A previous study demonstrated that 64-row
MDCT coronary angiography is cost-effective in patients with
a 10e50% pretest likelihood for CAD, whereas invasive coronary
angiography is the most cost-effective preferred approach in
patients with a likelihood for disease >60%.16 Another study
found 64-row MDCT to be more cost-effective than invasive
coronary angiography even up to a pretest likelihood for CAD of
86%.17 However, these studies applied different cost-accounting
practices and largely overestimated the costs of invasive coro-
nary angiography or the rate of severe complications associated
with elective cardiac catheterisation.16 17 Based on our own
calculations and in comparison with the available studies, we
found the threshold value for cost-effectiveness of DSCT coro-
nary angiography somewhat lower (up to 40% disease preva-
lence). From a cost-effective point of view, our results indicate
that the range of patients eligible for CTcoronary angiography is
smaller than previously believed and that invasive coronary
angiography becomes the more cost-effective diagnostic
approach at a disease prevalence >55%. These findings are
supported by recent guidelines on the assessment and diagnosis
of recent onset chest pain issued by the National Institute for
Health and Clinical Excellence.49 According to National Insti-
tute for Health and Clinical Excellence guidelines, CT coronary
angiography is recommended if a patient has a 10e29% pretest
likelihood for CAD. The guideline further recommends invasive
coronary angiography as the most cost-effective first test if the
likelihood of CAD is >61%.49
Our study has potential limitations. First, patients were not
randomised as to the order of imaging studies. However, DSCT
and invasive coronary angiography were interpreted by readers
who were blinded to the results of the other imaging study, and
thus, it is unlikely that any bias was introduced. Second, inva-
sive functional evaluation of coronary stenoses and subsequent
planning of coronary revascularisation were beyond the scope of
the current study and would require another cost-effectiveness
analysis with that specific objective.
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Clinical implications
Our analysis shows cost-effectiveness of DSCT coronary angi-
ography for diagnosing CAD in patients suspected as having this
disease and those with an intermediate pretest likelihood for
CAD. One has to take into account though that pretest likeli-
hood and prevalence do not necessarily mean the same thing.50
The global prevalence of CAD in our cohort is 24%, which is still
in agreement with a pretest likelihood at the lower end of
intermediate risk. However, as an intermediate pretest likelihood
generally ranges from 20% to 80%, there may be situations in
which the prevalence of CAD exceeds 55% and DSCT coronary
angiography is no longer cost-effective. Thus, the most impor-
tant step for physicians in selecting the appropriate diagnostic
approach (DSCT vs invasive coronary angiography) is based on
a clinical estimation of disease likelihood. The score by Morise
et al provides an easy, memorable and accurate method for
categorising and subcategorising patients with suspected CAD
into probability groups upon which decisions concerning diag-
nostic testing could be based.21 Although invasive coronary
angiography remains the gold standard for diagnosing CAD,
carefully performed DSCT coronary angiography may be an
economically efficient alternative to invasive angiography,
especially in ruling out CAD in patients with an intermediate
pretest likelihood.
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